CG
NMTR

Cutler Group’s 9 Meters Biopharma NMTR Stock Holding History

Cutler Group’s Portfolio NMTR Stock Details NMTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-155
Closed -$1K – 4961
2019
Q1 		$1K Buy
+155
New +$6.7K ﹤0.01% 3862
2018
Q4 		– Sell
-400
Closed -$2K – 4796
2018
Q3 		$2K Buy
400
+195
+95% +$33.5K ﹤0.01% 3631
2018
Q2 		$12K Buy
+205
New +$75.4K ﹤0.01% 2564

Other funds holding NMTR

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
ODFS
O'Donnell Financial Services San Rafael, California $290M AUM 15.6% 1-Year Est. Return

Cutler Group's NMTR Position: Q4 2022 in Review

Cutler Group sold out of 9 Meters Biopharma (NMTR) in Q4 2022, closing a stake of 220 shares.

Cutler Group first reported a position in NMTR in Q2 2018 and held it in 18 quarters. The position peaked at $58K in Q2 2018. 42 funds tracked by Wall St. Rank hold NMTR as of Q4 2022.

  • Cutler Group reported no remaining 9 Meters Biopharma position as of Q4 2022 after selling out during the quarter.
  • Cutler Group sold 220 9 Meters Biopharma shares in Q4 2022.
  • Cutler Group first reported a position in 9 Meters Biopharma in Q2 2018 and held it in 18 quarters.
  • Cutler Group's 9 Meters Biopharma position peaked at $58K in Q2 2018.
  • 42 funds tracked by Wall St. Rank held 9 Meters Biopharma as of Q4 2022.

Based on Cutler Group's 13F filing for Q4 2022, filed 7 Feb 2023.